-
公开(公告)号：US20160333377A1
公开(公告)日：2016-11-17
申请号：US15152960
申请日：2016-05-12
CPC分类号： C12N15/907 , A61K38/465 , A61K48/005 , A61P35/00 , C12N7/045 , C12N15/113 , C12N15/86 , C12N15/8616 , C12N2310/20 , C12N2750/14143 , C12N2800/80
摘要： Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.
摘要翻译： 本文公开了用于基因组编辑的基于核酸酶的系统和使用该系统进行基因组编辑的方法。 此外，还公开了当使用腺相关病毒载体（AAV）在辅助蛋白存在下表达基于CRISPR / Cas9的基因组编辑所需的指导RNA时，以最小的毒性增强原代人细胞中Cas9介导的基因编辑效率的方法 。
-
22.发明公开公开(公告)号：US20240316310A1
公开(公告)日：2024-09-26
申请号：US18608428
申请日：2024-03-18
申请人： University of Washington , SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
发明人： Courtnie Paschall , Jeffrey Andrew Herron , Emmanuel Tanumihardja , Rajesh P.N. Rao , Jason Scott Hauptman , Jeffrey G. Ojemann
IPC分类号： A61M21/02
CPC分类号： A61M21/02 , A61M2205/04 , A61M2205/33 , A61M2210/0693 , A61M2230/63
摘要： An extended reality (XR) neural perceptual feedback (NPF) system includes an XR system and a neural interface. The XR system presents a virtual environment to the user and monitors the user's interactions with the virtual environment. Based on the interaction with the virtual environment, the neural interface applies stimulation to the nervous system of the user. For example, a stimulation pattern may be selected based on the type of interaction, what type of virtual object the interaction was with, or combinations thereof. The stimulation may cause a percept in the user, allowing them to have perceptual feedback from interacting with the virtual environment. The neural interface may also be used to direct interactions within the virtual environment, for example using neural signal decoding to determine how to update the virtual environment.
-
公开(公告)号：US20240075069A1
公开(公告)日：2024-03-07
申请号：US18459302
申请日：2023-08-31
申请人： ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION , SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
发明人： Philip Stewart LOW , Haiyan CHU , Yingjuan June LU , Christopher Paul LEAMON , Leroy W. WHEELER, II , Michael C. JENSEN , James MATTHAEI
IPC分类号： A61K35/17 , A61K9/00 , A61K31/365 , A61K31/519 , A61K38/17 , A61P35/00 , C07K14/725 , C07K16/44 , C07K16/46 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0053 , A61K31/365 , A61K31/519 , A61K38/1774 , A61P35/00 , C07K14/7051 , C07K16/44 , C07K16/46 , C12N5/0638 , C07K2317/622
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
24.发明公开公开(公告)号：US20240033300A1
公开(公告)日：2024-02-01
申请号：US18336248
申请日：2023-06-16
IPC分类号： A61K35/545 , C12N15/10 , C12N15/66 , C12N15/85 , A61K48/00 , A61P37/06 , A61K38/20 , C12N5/0789 , C12N15/52
CPC分类号： A61K35/545 , C12N15/102 , C12N15/66 , C12N15/85 , A61K48/00 , A61P37/06 , A61K38/2013 , C12N5/0647 , C12N15/52
摘要： Disclosed are methods of making a genetically cell that expressed FOXP3 and methods of treatment. In some embodiments, the method comprises providing a first nucleotide sequence, wherein the first nucleotide sequence comprises a coding strand, the coding strand comprising one or more regulatory elements and a FOXP3 gene or portion thereof providing a nuclease and performing a gene editing process on the first nucleotide sequence, which edits said one or more regulatory elements, and optionally edits the FOXP3 gene or portion thereof. Methods of treating a subject suffering from an autoimmune disease and subjects suffering the effects of organ transplantation are also provided.
-
公开(公告)号：US20230374104A1
公开(公告)日：2023-11-23
申请号：US18030476
申请日：2021-10-07
发明人： Michael C. Jensen , Adam Johnson , James Rosser
IPC分类号： C07K14/705 , C07K14/725
CPC分类号： C07K14/70596 , C07K14/7051
摘要： Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a programmed cell death protein 1 (PD 1) extracellular domain and an intracellular immunostimulatory domain. Some embodiments include a cell containing a PD 1 chimeric polypeptide and a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a ligand binding domain capable of specifically binding to a target antigen on a solid tumor. More embodiments relate to therapies to treat, inhibit or ameliorate certain disorders, such as a cancer, such as a solid tumor.
-
公开(公告)号：US20230068879A1
公开(公告)日：2023-03-02
申请号：US17758959
申请日：2021-02-02
IPC分类号： C07K14/725
摘要： Embodiments provided herein include methods and compositions comprising anti-dinitrophenol chimeric antigen receptors (CARs). Some embodiments include nucleic acids encoding such CARs, polypeptides encoded by such nucleic acids, cells comprising such nucleic acids or polypeptides, and methods utilizing such cells. Some embodiments also include the use of dinitrophenol (DNP) and derivatives thereof.
-
27.发明申请公开(公告)号：US20230054471A1
公开(公告)日：2023-02-23
申请号：US17811685
申请日：2022-07-11
摘要： Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
-
公开(公告)号：US20220195441A1
公开(公告)日：2022-06-23
申请号：US17594542
申请日：2020-04-21
申请人： Seattle Children's Hospital (dba Seattle Children's Research Institute) , Fred Hutchinson Cancer Research Center
IPC分类号： C12N15/62 , C07K16/28 , C07K14/705 , C07K14/725 , C07K14/71
摘要： Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CAR)s which specifically bind to an epitope of CD33, such as an epitope encoded by exon 2 of CD33. Some embodiments include the use of such CARs for effective and safe therapies for myeloid leukemias, such as acute myeloid leukemia and chronic myeloid leukemia.
-
公开(公告)号：US20220125951A1
公开(公告)日：2022-04-28
申请号：US17424140
申请日：2020-01-30
摘要： Some embodiments of the methods and compositions provided herein relate to transgenes comprising regulatory elements capable of inducing specific transcription of an operably-linked therapeutic payload in a cell in an in vivo microenvironment. In some embodiments, the regulatory elements are responsive to endogenous stimuli of the microenvironment. In some embodiments, the regulatory elements are response to stimuli from chimeric receptors in the cell.
-
30.发明申请公开(公告)号：US20210317407A1
公开(公告)日：2021-10-14
申请号：US17265484
申请日：2019-08-02
IPC分类号： C12N5/0783 , A61K35/17 , C07K16/44 , C07K14/73 , C07K14/705 , C07K16/28
摘要： Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.034 秒)
